INCR Stock Overview
Engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
InterCure Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪1.70 |
| 52 Week High | ₪3.72 |
| 52 Week Low | ₪1.17 |
| Beta | 0.14 |
| 1 Month Change | 25.93% |
| 3 Month Change | -9.09% |
| 1 Year Change | 38.21% |
| 3 Year Change | -75.50% |
| 5 Year Change | 37.10% |
| Change since IPO | -32.27% |
Recent News & Updates
InterCure: A Cannabis Industry Leader Still Flying Under The Radar
Jun 30InterCure: Bargain Israel Cannabis Play
Apr 22Recent updates
InterCure: A Cannabis Industry Leader Still Flying Under The Radar
Jun 30InterCure: Bargain Israel Cannabis Play
Apr 22InterCure: A Leader In Global Cannabis
Sep 06InterCure reports Q2 results
Aug 15InterCure Is Growing In The Massive Global Cannabis Market
Jun 07IntureCure: Israel Recreation Cannabis Boom On The Way
Feb 16InterCure Chairman Ehud Barak, CEO Alex Rabinovitch - Israel Cannabis And Beyond (Video)
Nov 08InterCure: Internationally Profitable Cannabis (Podcast Transcript)
Sep 19InterCure: Ignored Uplisting
Sep 09Shareholder Returns
| INCR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 18.9% | 1.6% | -2.2% |
| 1Y | 38.2% | 9.7% | 23.9% |
Return vs Industry: INCR exceeded the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: INCR exceeded the US Market which returned 23.9% over the past year.
Price Volatility
| INCR volatility | |
|---|---|
| INCR Average Weekly Movement | 12.4% |
| Pharmaceuticals Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INCR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: INCR's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 270 | Alex Rabinovich | www.intercure.co |
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector.
InterCure Ltd. Fundamentals Summary
| INCR fundamental statistics | |
|---|---|
| Market cap | US$80.22m |
| Earnings (TTM) | -US$17.99m |
| Revenue (TTM) | US$74.76m |
1.1x
P/S Ratio-4.5x
P/E RatioIs INCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INCR income statement (TTM) | |
|---|---|
| Revenue | ₪272.67m |
| Cost of Revenue | ₪194.70m |
| Gross Profit | ₪77.98m |
| Other Expenses | ₪143.60m |
| Earnings | -₪65.62m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.43 |
| Gross Margin | 28.60% |
| Net Profit Margin | -24.07% |
| Debt/Equity Ratio | 28.8% |
How did INCR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 22:50 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
InterCure Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matt Bottomley | Canaccord Genuity |
| Vivien Azer | TD Cowen |